Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth
- PMID: 3802015
- DOI: 10.1002/1097-0142(19870115)59:2<281::aid-cncr2820590218>3.0.co;2-a
Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth
Abstract
The proliferative response of human mammary epithelial cells cultured in medium containing oral contraceptive steroids, singly and in combination, was measured. Cells came from 59 normal, nonmalignant atypical, and malignant breast tissue specimens. Growth of most cultures was stimulated by the estrogens 17 beta-estradiol and ethinyl estradiol, and any combination containing ethinyl estradiol. Most (75%) malignant specimens were stimulated by one or more of the progestins, whereas none of the nonmalignant cells were. For two of the estrogen/progestin combinations found in many birth control pills, malignant cells were stimulated to grow faster than nonmalignant cells. It was concluded that oral contraceptive steroids can stimulate the growth of mammary epithelia in cell culture and might do the same in vivo. These data corroborate epidemiologic data which suggest oral contraceptives might act as tumor promoters, especially in the older user, who is more likely to have malignant cells already present in the breast.
Similar articles
-
A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.Am J Obstet Gynecol. 1993 Nov;169(5):1183-9. doi: 10.1016/0002-9378(93)90279-r. Am J Obstet Gynecol. 1993. PMID: 8238183
-
Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.Am J Obstet Gynecol. 1980 Apr 1;136(7):920-31. doi: 10.1016/0002-9378(80)91052-2. Am J Obstet Gynecol. 1980. PMID: 6767404 Clinical Trial.
-
Insulin resistance, secretion, and metabolism in users of oral contraceptives.J Clin Endocrinol Metab. 1992 Jan;74(1):64-70. doi: 10.1210/jcem.74.1.1530790. J Clin Endocrinol Metab. 1992. PMID: 1530790
-
Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation.Expert Rev Clin Pharmacol. 2018 Nov;11(11):1085-1098. doi: 10.1080/17512433.2018.1536544. Epub 2018 Nov 6. Expert Rev Clin Pharmacol. 2018. PMID: 30325245 Review.
-
Exogenous progestins and breast cancer.Epidemiol Rev. 1993;15(1):98-107. doi: 10.1093/oxfordjournals.epirev.a036120. Epidemiol Rev. 1993. PMID: 8405216 Review.
Cited by
-
Comment on 'Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells'.Breast Cancer Res Treat. 1988 Sep;12(1):81-2. doi: 10.1007/BF01805744. Breast Cancer Res Treat. 1988. PMID: 3196889 No abstract available.
-
Contraceptive steroids and the mammary gland: is there a hazard?--Insights from animal studies.Breast Cancer Res Treat. 1992;23(1-2):29-41. doi: 10.1007/BF01831473. Breast Cancer Res Treat. 1992. PMID: 1446049 Review.
-
Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.Br J Cancer. 1989 Jan;59(1):119-25. doi: 10.1038/bjc.1989.24. Br J Cancer. 1989. PMID: 2757918 Free PMC article.
-
Routine culturing of normal, dysplastic and malignant human mammary epithelial cells from small tissue samples.In Vitro Cell Dev Biol. 1990 Dec;26(12):1186-94. doi: 10.1007/BF02623697. In Vitro Cell Dev Biol. 1990. PMID: 2079464
-
Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.Br J Cancer. 1994 Aug;70(2):270-7. doi: 10.1038/bjc.1994.291. Br J Cancer. 1994. PMID: 8054275 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical